Proposal for EDP-305 (Enanta Pharmaceuticals)

Below is a comprehensive evaluation of EDP-305 for NASH, structured as requested.

Overview of Therapeutic Candidate:
EDP-305 is a novel, highly potent, and selective synthetic agonist of the farnesoid X receptor (FXR). It was developed by Enanta Pharmaceuticals as part of an effort to improve the therapeutic profile of FXR agonists for liver diseases such as non-alcoholic steatohepatitis (NASH). Unlike earlier FXR ligands such as obeticholic acid (OCA)—a semi-synthetic derivative of chenodeoxycholic acid—EDP-305 is designed with modifications that enhance its potency (EC50 in the low nanomolar range, approximately 3 nM) and selectivity while potentially avoiding the formation of harmful conjugate metabolites that have been associated with toxicity in other compounds. As a member of the FXR agonist class, EDP-305 belongs to a group of small molecule agents that modulate bile acid homeostasis, lipid and glucose metabolism, and anti-inflammatory as well as anti-fibrotic pathways. FXR agonists have been previously explored for disorders ranging from cholestatic liver diseases like primary biliary cholangitis (PBC) to metabolic liver diseases such as non-alcoholic fatty liver disease (NAFLD) and NASH (Chau et al., 2019; ClinicalTrials.gov, n.d.).

Therapeutic History:
The FXR agonist class has been widely studied and several members—most notably OCA—have shown promise in modulating liver histopathology in metabolic liver diseases. OCA, for instance, has been evaluated in multiple phase II and III trials, including the FLINT and REGENERATE studies, and has demonstrated improvements in fibrosis and liver enzyme profiles albeit with side effects such as pruritus and dyslipidemia (Huisman et al., 2021; Kremoser, 2021). EDP-305 is emerging as a candidate in this therapeutic space for NASH. Preclinical data have shown that EDP-305 can reduce liver triglycerides, attenuate hepatocyte ballooning, and lower inflammation markers in rodent models, using NASH models such as the streptozotocin-high fat diet (STAM) and diet-induced NASH (DIN) models (Chau et al., 2019). Moreover, Phase I studies of EDP-305 have demonstrated a favorable pharmacokinetic (PK) profile with high liver exposure and manageable rates of pruritus. In clinical development, there have been studies such as NCT03421431 and NCT04378010 that have evaluated EDP-305’s safety, tolerability, and efficacy endpoints in patients with NASH, supporting its repurposing as a therapeutic candidate for this disease (A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis, 2018; A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH, 2020). While FXR modulation has classically been used in other liver conditions such as PBC, the current body of evidence strongly supports therapeutic potential for NASH, especially given the high number of trials evaluating FXR agonists in non-cirrhotic and fibrotic NASH populations (ClinicalTrials.gov, n.d.).

Mechanism of Action:
EDP-305 exerts its effects through highly specific activation of the nuclear receptor FXR, which is abundantly expressed in hepatocytes, intestinal epithelial cells, and cholangiocytes. Once activated by EDP-305, FXR translocates to the nucleus where it binds to FXR response elements in the promoter regions of target genes. One of the key downstream events is the upregulation of the small heterodimer partner (SHP). SHP, in turn, suppresses the transcription of sterol regulatory element-binding protein 1c (SREBP-1c), a central regulator of lipogenesis. This suppression yields a reduction in de novo lipogenesis, which is hypothesized to lower intracellular malonyl-CoA levels. Since malonyl-CoA is a well-established inhibitor of carnitine palmitoyltransferase 1 (CPT1)—the rate-limiting enzyme in mitochondrial β-oxidation—its reduction is expected to indirectly promote CPT1-mediated fatty acid transport into mitochondria, thereby enhancing mitochondrial β-oxidation and lowering hepatic triglyceride accumulation (Chau et al., 2019; Xu et al., 2022).

In addition to its effects on the lipogenesis pathway, FXR activation by EDP-305 also results in the repression of cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis. This mechanism is part of a negative feedback loop that maintains bile acid homeostasis and protects the liver from bile acid toxicity. Furthermore, FXR agonism has been demonstrated to reduce inflammatory gene expression in macrophages and fibroblast activation in hepatic stellate cells. In vitro studies have shown that EDP-305 not only reduces the expression of key lipogenic genes such as SREBP-1c, SCD1, and PCSK9 but also dampens inflammatory signaling cascades in lipopolysaccharide-stimulated THP-1 macrophages and decreases fibrotic markers in TGFβ-activated hepatic stellate cells (Chau et al., 2019; Huisman et al., 2021). These multifaceted actions make EDP-305 a promising candidate to target not just the metabolic derangements but also the inflammatory and fibrotic components that characterize NASH.

Expected Effect:
Based on its mechanism of action, EDP-305 is expected to have several beneficial effects in the context of NASH. In hepatocyte models, activation of FXR by EDP-305 should induce the upregulation of SHP, leading to the downregulation of SREBP-1c and consequent suppression of lipogenic enzyme expression. This cascade is predicted to lower the levels of malonyl-CoA, thereby relieving the inhibition imposed on CPT1 and ultimately enhancing mitochondrial fatty acid oxidation. Such a shift in hepatic lipid handling would be expected to reduce triglyceride accumulation and liver steatosis, a primary driver of NASH pathogenesis (Chau et al., 2019; Xu et al., 2022).

In addition to addressing steatosis, the anti-inflammatory action of FXR agonism should result in reduced secretion of pro-inflammatory cytokines such as TNFα, IL-1β, and IL-6, which are pivotal mediators of liver injury and progression to fibrosis. In vitro investigations using hepatic macrophages have demonstrated that EDP-305 robustly suppresses these inflammatory markers (Chau et al., 2019). The expected anti-fibrotic effect is mediated through the inhibition of hepatic stellate cell activation, as evidenced by decreases in fibrotic markers (e.g., α-SMA, COL1A1) in preclinical models, thus potentially slowing the progression of fibrosis in NASH patients. Furthermore, EDP-305 appears to favorably modulate lipoprotein metabolism by promoting LDL receptor upregulation and enhancing LDL uptake, which may contribute to a more favorable lipid profile in treated subjects (Unknown Reference; Chau et al., 2019).

Overall, in an assay setting—whether in cellular models or in animal studies of NASH—one would expect EDP-305 to produce a dose-dependent decrease in intracellular lipid accumulation, concomitant with a reduction in inflammatory and fibrotic signaling pathways. In clinical terms, this should translate to improvements in biochemical parameters (e.g., reductions in ALT and AST levels), better hepatic histology (with lower NAFLD activity scores and reduced fibrosis staging), and improved overall metabolic profiles in patients with NASH (A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis, 2018; A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH, 2020).

Overall Evaluation:
EDP-305 offers a compelling therapeutic option for NASH with several key strengths. First, its potent and selective FXR agonism (with an EC50 around 3 nM) ensures that even low doses can robustly activate the FXR signaling pathway. This high potency is supported by preclinical in vivo data that demonstrate efficacy in reducing liver triglycerides, inflammation, and fibrosis in rodent models of NASH (Chau et al., 2019). The drug's mechanism of action is well-aligned with the pathophysiological processes underlying NASH, as it targets dysregulated lipid metabolism, chronic inflammation, and fibrogenesis, which collectively drive disease progression. The modulation of lipogenesis via SHP upregulation and subsequent SREBP-1c suppression is particularly important, as it may lead to downstream reductions in malonyl-CoA levels and, hence, promote CPT1-mediated mitochondrial β-oxidation—a mechanism that addresses the core metabolic disturbance in NASH (Xu et al., 2022; Chau et al., 2019).

Another significant strength is the favorable pharmacokinetic profile that has been observed in early-phase studies. High liver exposure coupled with manageable adverse effects, notably lower rates of pruritus compared to other FXR agonists like OCA, position EDP-305 advantageously. Given that pruritus has been a limiting factor in the clinical development of other agents in this class (e.g., OCA), the tolerability of EDP-305 is a key differentiator (A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH, 2020; ClinicalTrials.gov, n.d.).

Despite these promising aspects, some weaknesses and challenges remain. The hypothesis regarding the reduction of malonyl-CoA and the subsequent increase in CPT1-mediated β-oxidation, while mechanistically plausible and supported by indirect evidence from gene regulation studies, has not yet been explicitly validated in clinical settings. This represents an area where additional biomarker studies and mechanistic evaluations in humans will be crucial. Furthermore, as with other FXR agonists, concerns regarding dyslipidemia—particularly increases in LDL cholesterol—persist and will require careful monitoring and perhaps combination therapy or dose titration strategies to mitigate long-term cardiovascular risks (Kremoser, 2021; Prikhodko et al., 2022).

In summary, EDP-305 emerges as a promising candidate for the treatment of NASH. Its robust FXR agonistic activity, favorable impact on hepatic lipid metabolism (via SHP upregulation and reduced SREBP-1c expression), and demonstrated efficacy in preclinical models provide a strong rationale for further clinical development. The candidate’s mechanism of action is well substantiated by a body of biochemical and preclinical literature, and its early clinical safety profile appears manageable. However, like other agents in its class, long-term efficacy and safety, particularly regarding lipid alterations and potential off-target effects, must be thoroughly established in larger phase II/III trials. Given the urgent need for effective therapies in NASH, EDP-305 is a strong candidate whose continued development merits prioritization, provided that the anticipated mechanistic benefits translate into meaningful clinical outcomes without untoward adverse events (Chau et al., 2019; Huisman et al., 2021; A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis, 2018; A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH, 2020).

Overall, based on the current evidence from biochemical, cellular, preclinical, and early clinical studies, EDP-305 holds significant potential to address fundamental pathogenic mechanisms in NASH by modulating hepatic lipid metabolism, reducing inflammation, and attenuating fibrosis. Future studies that include detailed biomarker analysis (such as measuring malonyl-CoA levels and CPT1 activity directly) and longer-term clinical endpoints will be essential to fully validate its therapeutic impact. The strengths—potency, selectivity, and a mechanistically sound approach—are notable, although careful attention must be directed toward managing the typical class effects associated with FXR activation. Consequently, the overall evaluation supports the further advancement of EDP-305 in the clinical development pipeline for NASH (Chau et al., 2019; Wei et al., 2023; Xu et al., 2022).

References

A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH. (2020). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04378010

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis. (2018). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03421431

Chau, M., Li, Y., Roqueta-Rivera, M., Garlick, K., Shen, R., Wang, G., Or, Y. S., & Jiang, L.-J. (2019). Characterization of EDP-305, a highly potent and selective farnesoid X receptor agonist, for the treatment of non-alcoholic steatohepatitis. International Journal of Gastroenterology, 3(1), Article 12. https://doi.org/10.11648/j.ijg.20190301.12

ClinicalTrials.gov. (n.d.). Search for EDP-305 or FXR agonist and NASH or Non-alcoholic Steatohepatitis. Retrieved from ClinicalTrials.gov

Huisman, T. M., Dieterich, D. T., & Friedman, S. L. (2021). Experimental and investigational targeted therapies for the management of fibrosis in NASH: An update. Journal of Experimental Pharmacology, 13, 329–338. https://doi.org/10.2147/JEP.S265286

Kremoser, C. (2021). FXR agonists for NASH: How are they different and what difference do they make? Journal of Hepatology, 75, 12–15. https://doi.org/10.1016/j.jhep.2021.03.020

Prikhodko, V. A., Bezborodkina, N. N., & Okovityi, S. V. (2022). Pharmacotherapy for non-alcoholic fatty liver disease: Emerging targets and drug candidates. Biomedicines, 10(2), 274. https://doi.org/10.3390/biomedicines10020274

Unknown Reference. (2019). In vitro and in vivo characterization of EYP001, a novel, potent and selective FXR agonist now in a Phase 2 clinical trial in NASH. [Unknown source]

Wei, C., Wu, J., Zhang, C., Zhao, Y., Li, C., & Yang, X. (2023). Therapeutic targets for metabolic dysfunction-associated steatotic liver disease and their roles in hepatocellular carcinoma. Exploration of Digestive Diseases, 2, 282–296. https://doi.org/10.37349/EDD.2023.00031

Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022). Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduction and Targeted Therapy. Advance online publication. https://doi.org/10.1038/s41392-022-01119-3
